NCCN Webinar: Maintenance Therapy for Non-Small Cell Lung Cancer (NSCLC)

Educational Events & Programs
NCCN Webinar: Maintenance Therapy for Non-Small Cell Lung Cancer (NSCLC)
Program Overview

This one-hour webinar will educate participants on how to outline treatment approaches for patients after initial therapy for advanced NSCLC, identify patients that are most likely to benefit from maintenance therapy, and summarize the risks and benefits associated with maintenance therapy.

Lung cancer is often diagnosed in the advanced stage where there is a poor prognosis. There are different therapeutic approaches currently available for patients after initial treatment of advanced non-small cell lung cancer (NSCLC), but there is little scientific data to support one approach as the standard of care. Clinicians need to integrate a variety of factors into their clinical decision making to provide the best treatment plan for the patient. These factors include: risks and benefits of administering maintenance therapy, histologic characteristics of the tumor, patient and treatment-related factors, and goals of therapy. It is crucial that the clinician have a thorough knowledge of the associated factors for clinical decision making to optimize the desired clinical outcome for the patient.
Presenters:

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Webinar Schedule*:

* Wednesday, September 22, 2010 • 2:00 – 3:00 PM EDT
* Friday, September 24, 2010 • 3:00 – 4:00 PM EDT
* Friday, October 1, 2010 • 1:00 – 2:00 PM EDT
* Friday, October 22, 2010 • 2:00 – 3:00 PM EDT

*Please note: each scheduled webinar will include the same content, individuals only need to register for one session.
Educational Objectives:

* Outline treatment approaches for patients after initial therapy for advanced NSCLC
* Identify patients that are most likely to benefit from maintenance therapy
* Summarize the risks and benefits associated with maintenance therapy

Intended Audience:

This educational program is designed to meet the educational needs of oncologists, nurses, and other health care professionals who manage patients with NSCLC.
Registration:

There is no fee for this educational webinar. If cancellation is necessary, please notify NCCN.
Accreditation:

Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Faculty Disclosure:

All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.\
Supporters:

This activity is supported by an educational grant from Genentech BioOncology and OSI Oncology.
Additional Information Regarding Call-in Numbers for WebEx Sessions

Global call-in numbers
Toll-free dialing restrictions

open here please:
NCCN Webinar: Maintenance Therapy for Non-Small Cell Lung Cancer (NSCLC)